GlobeNewswire·Aug 13, 2026, 8:30 AM ET

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathy has enrolled 217 patients with top-line results expected in fall 2026.
A Phase 2b Long-Term Extension Study has commenced to assess Halneuron® pain reduction over a three-month treatment period.
Iain Dukes, D.Phil., a Venture Partner at OrbiMed, was appointed Chair of the Scientific Advisory Board.
A worldwide development & commercialization partnership for legacy antiviral assets was announced with Dogwood Therapeutics, offering potential value up to $100M to Dogwood & its CVR Holders.
SP16 received IND approval from the FDA for a study on chemotherapy-induced pain & peripheral neuropathy, fully funded by the National Cancer Institute.
Cash on hand totaled $9.6 million, providing operational runway through the Phase 2b readout in Q4 2026.
Research & development expenses for Q2 2026 were $3.2 million, while general & administrative expenses were $1.6 million.
The company recognized a net non-cash IPR&D impairment charge of $6.7 million due to a decline in stock price.
Net loss attributable to common stockholders for Q2 2026 was $11.5 million, or $0.34 per share.